AIRS Airsculpt Technologies, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1870940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.3%
TTM net income YoY47.7%
TTM EPS YoY60.0%
Revenue 3-yr CAGR-7.9%
Net income 3-yr CAGR—
Margins
Gross margin60.2%
Operating margin-4.7%
Net margin-6.4%
FCF margin-1.7%
EBITDA margin3.4%
Returns
ROE-10.1%
ROA-5.0%
ROIC (approx.)-4.2%
Asset turnover0.79x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.35x
Current ratio0.85x
Interest coverage-1.40x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $151.82M | $180.35M |
| Cost of revenue | $61.69M | $71.15M |
| Gross profit | $90.13M | $109.20M |
| SG&A expense | $82.18M | $98.88M |
| Operating income | -$11.56M | -$1.58M |
| Interest expense | $6.08M | $6.25M |
| Pretax income | -$17.64M | -$7.83M |
| Income tax | -$5.97M | $188,000 |
| Net income | -$11.67M | -$8.02M |
| EBITDA | $1.22M | $10.30M |
| EPS (basic) | -0.19 | -0.14 |
| EPS (diluted) | -0.19 | -0.14 |
| Weighted avg. shares (diluted) | 60.45M | 57.69M |
| Balance sheet | ||
| Cash & equivalents | $8.45M | $8.23M |
| Current assets | $15.46M | $17.12M |
| PP&E, net | $27.81M | $37.47M |
| Goodwill | $81.73M | $81.73M |
| Intangibles | $36.84M | $41.59M |
| Total assets | $187.30M | $212.78M |
| Current liabilities | $27.90M | $28.95M |
| Short-term debt | $5.46M | $4.25M |
| Long-term debt | $50.59M | $65.46M |
| Total debt | $56.05M | $69.71M |
| Total liabilities | $99.59M | $134.59M |
| Shareholders' equity | $87.71M | $78.19M |
| Net debt | $47.60M | $61.47M |
| Shares outstanding | 64.54M | 58.37M |
| Cash flow statement | ||
| Operating cash flow | $3.10M | $11.35M |
| Capital expenditure | $2.40M | $14.01M |
| Free cash flow | $692,000 | -$2.66M |
| Investing cash flow | -$2.40M | -$14.01M |
| Financing cash flow | -$478,000 | $630,000 |
| Depreciation & amortization | $12.78M | $11.89M |
| Stock-based compensation | $2.33M | $3.76M |
| Dividends paid | $0 | $252,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.